Richard Ringler Fabian Acquires 10,000 Shares of Profound Medical (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) insider Richard Ringler Fabian acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were bought at an average cost of C$8.31 per share, for a total transaction of C$83,100.00. Following the acquisition, the insider directly owned 10,000 shares in the company, valued at C$83,100. This represents a ∞ increase in their position.

Profound Medical Stock Up 1.0%

Shares of TSE PRN opened at C$8.31 on Friday. Profound Medical Corp. has a 52 week low of C$5.70 and a 52 week high of C$12.40. The business has a 50-day simple moving average of C$9.62 and a two-hundred day simple moving average of C$9.29. The company has a quick ratio of 14.98, a current ratio of 6.46 and a debt-to-equity ratio of 14.82. The company has a market cap of C$303.65 million, a P/E ratio of -8.39 and a beta of 1.06.

Profound Medical (TSE:PRN) last announced its quarterly earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share for the quarter. Profound Medical had a negative net margin of 170.92% and a negative return on equity of 62.45%. The company had revenue of C$3.53 million for the quarter. Research analysts anticipate that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Raymond James Financial upgraded shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, July 27th. Five analysts have rated the stock with a Buy rating, nineteen have assigned a Moderate Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Profound Medical currently has an average rating of “Moderate Buy” and an average target price of C$8.31.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.